[go: up one dir, main page]

MX2018000091A - Virus de la enteritis del pato y usos del mismo. - Google Patents

Virus de la enteritis del pato y usos del mismo.

Info

Publication number
MX2018000091A
MX2018000091A MX2018000091A MX2018000091A MX2018000091A MX 2018000091 A MX2018000091 A MX 2018000091A MX 2018000091 A MX2018000091 A MX 2018000091A MX 2018000091 A MX2018000091 A MX 2018000091A MX 2018000091 A MX2018000091 A MX 2018000091A
Authority
MX
Mexico
Prior art keywords
duct
same
enteritis
viruses
enteritis viruses
Prior art date
Application number
MX2018000091A
Other languages
English (en)
Other versions
MX381252B (es
Inventor
Saitoh Shuji
Yukari Saeki
Original Assignee
Ceva Sante Animale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceva Sante Animale filed Critical Ceva Sante Animale
Publication of MX2018000091A publication Critical patent/MX2018000091A/es
Publication of MX381252B publication Critical patent/MX381252B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16361—Methods of inactivation or attenuation
    • C12N2710/16362—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con DEV y los usos del mismo. La invención es particularmente adecuada para vacunar aves de corral contra patógenos aviares.
MX2018000091A 2015-06-30 2016-06-29 Virus de la enteritis del pato y usos del mismo. MX381252B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15174515 2015-06-30
PCT/EP2016/065132 WO2017001469A1 (en) 2015-06-30 2016-06-29 Duck enteritis virus and the uses thereof

Publications (2)

Publication Number Publication Date
MX2018000091A true MX2018000091A (es) 2018-02-19
MX381252B MX381252B (es) 2025-03-11

Family

ID=53496539

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000091A MX381252B (es) 2015-06-30 2016-06-29 Virus de la enteritis del pato y usos del mismo.

Country Status (10)

Country Link
US (5) US10202582B2 (es)
EP (1) EP3317406A1 (es)
JP (1) JP6802813B2 (es)
CN (1) CN108368488B (es)
CA (1) CA2992158C (es)
MX (1) MX381252B (es)
PE (1) PE20180463A1 (es)
RU (1) RU2721575C2 (es)
UA (1) UA122339C2 (es)
WO (1) WO2017001469A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202582B2 (en) * 2015-06-30 2019-02-12 Ceva Sante Animale Duck enteritis virus and the uses thereof
EP3263129A1 (en) * 2016-06-29 2018-01-03 Ceva Sante Animale Duck enteritis virus and the uses thereof
CN110904058B (zh) * 2018-09-14 2023-03-07 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 重组鸭瘟病毒疫苗及其构建方法和应用
WO2021202423A1 (en) * 2020-03-31 2021-10-07 Grail, Inc. Cancer classification with genomic region modeling
CN113249340B (zh) * 2020-08-19 2022-07-19 浙江省农业科学院 一株双色荧光蛋白标记鸭瘟病毒及其构建方法和应用
WO2025044920A2 (en) * 2023-08-25 2025-03-06 Boehringer Ingelheim Vetmedica (China) Co., Ltd. New dev vectors for avian vaccines
TW202523838A (zh) * 2023-08-25 2025-06-16 大陸商勃林格殷格翰動物保健（中國）有限公司 新型dev載體
WO2025044922A2 (en) * 2023-08-25 2025-03-06 Boehringer Ingelheim Vetmedica (China) Co., Ltd. Vectored dev avian influenza h9 vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757061B1 (fr) 1996-12-16 1999-03-26 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
EP2140879A1 (en) * 2001-05-09 2010-01-06 M'S Science Corporation Composition and method for treating cancer using herpes virus
FR2916759B1 (fr) * 2007-05-29 2009-07-10 Adisseo France Sas Soc Par Act Peptide rumc presentant une activite antimicrobienne
CN102277368B (zh) * 2010-06-13 2013-12-25 中国农业科学院哈尔滨兽医研究所 鸭病毒性肠炎病毒感染性重组克隆系统及构建方法和应用
CN102533674B (zh) * 2010-12-08 2014-05-14 中国农业科学院哈尔滨兽医研究所 表达禽流感病毒血凝素基因的重组鸭病毒性肠炎病毒疫苗株及其构建方法和应用
CN103667351B (zh) * 2012-09-10 2017-01-25 中国农业科学院哈尔滨兽医研究所 以鸭病毒性肠炎病毒疫苗株为载体的重组病毒疫苗在鸡形目禽类中的应用
WO2014036735A1 (zh) 2012-09-10 2014-03-13 中国农业科学院哈尔滨兽医研究所 鸭病毒性肠炎病毒疫苗株作为表达载体在制备预防鸡形目禽类疾病的重组病毒疫苗中的应用
US10202582B2 (en) * 2015-06-30 2019-02-12 Ceva Sante Animale Duck enteritis virus and the uses thereof
EP3263129A1 (en) 2016-06-29 2018-01-03 Ceva Sante Animale Duck enteritis virus and the uses thereof

Also Published As

Publication number Publication date
MX381252B (es) 2025-03-11
PE20180463A1 (es) 2018-03-06
US20190136209A1 (en) 2019-05-09
UA122339C2 (uk) 2020-10-26
JP6802813B2 (ja) 2020-12-23
CA2992158C (en) 2023-11-21
US10717967B2 (en) 2020-07-21
US10704028B2 (en) 2020-07-07
US20190144835A1 (en) 2019-05-16
US10711255B2 (en) 2020-07-14
RU2018103145A3 (es) 2019-11-20
US10711254B2 (en) 2020-07-14
CN108368488A (zh) 2018-08-03
BR112017028420A2 (pt) 2018-08-28
US20190144836A1 (en) 2019-05-16
US20180187164A1 (en) 2018-07-05
EP3317406A1 (en) 2018-05-09
CA2992158A1 (en) 2017-01-05
CN108368488B (zh) 2022-04-05
US10202582B2 (en) 2019-02-12
US20190136208A1 (en) 2019-05-09
JP2018519826A (ja) 2018-07-26
WO2017001469A1 (en) 2017-01-05
RU2018103145A (ru) 2019-07-30
RU2721575C2 (ru) 2020-05-20

Similar Documents

Publication Publication Date Title
MX2018000091A (es) Virus de la enteritis del pato y usos del mismo.
MX388489B (es) Virus de enteritis de pato y usos del mismo
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
IL266119A (en) Antiviral compositions for the treatment of infections linked to coronaviruses
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
JOP20190256A1 (ar) فيروسات داء نيوكاسل واستخداماتها
DK3597646T3 (da) Terapeutiske forbindelser egnede til den profylaktiske eller terapeutiske behandling af en hiv-virusinfektion
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
HRP20190352T1 (hr) Novi 6-kondenzirani heteroarildihidropirimidini za liječenje i profilaksu infekcije virusom hepatitisa b
PL3684377T3 (pl) Sposoby leczenia zakażenia wirusem zapalenia wątroby typu b
MX392098B (es) Anticuerpos neutralizantes de poliomavirus.
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
MX2016010651A (es) Vacunas de virus aviar que son estables en liquido.
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
CL2017000063A1 (es) Vacunas contra virus influenza y usos de las mismas
EP3509596C0 (en) NORKETOTIFEN FOR THE TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION
MX380393B (es) Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas.
BR112016024096A2 (pt) novo bacteriófago e composição compreendendo o mesmo
MX380682B (es) Nueva especie de tobamovirus.
PH12016502001A1 (en) Novel bacteriophage and composition comprising same
EP3317290A4 (en) COMPOSITIONS AND METHOD FOR TREATING VIRUS INFECTION